Table 5.

PICOS of this study.

P (patients): patients with MBC

I (intervention): nab-paclitaxel

C (comparators): solvent-based taxanes (sb-paclitaxel, docetaxel)

O (outcomes): primary end point; ORR and DCR

secondary end points; PFS, OS, AEs, and DDR

S (study design): RCTs on the efficacy and adverse events comparing nab–paclitaxel-based chemotherapy with solvent-based taxane chemotherapy

MBC: metastatic breast cancer, ORR: overall response rate, DCR: disease control rate, PFS: progression-free survival, OS: overall survival, AE: adverse events, DDR: dose discontinuation rate, RCT: randomized clinical trial